GSK

News
GSK files Blenrep in EU, seeking return to market

GSK files Blenrep in EU, seeking return to market

Less than two years after pulling multiple myeloma therapy Blenrep off most markets around the world, GSK has filed for approval of the drug in the EU once again, hoping to restore its bloc

News
CureVac

GSK goes all-in on CureVac’s mRNA vaccines

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and

R&D
Dr Suzanne Trudel at ASCO 2024

ASCO 2024 - Suzanne Trudel

Sometimes getting a new drug to market is a relatively straight line, but sometimes it’s a winding road.